Osteoporosis Prevention and Management

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Osteoporosis, defined by BMD at the hip or lumbar spine that is less than or equal to 2.5 standard deviations below the mean BMD of a young-adult reference population, is the most common bone disease in humans affecting both sexes and all races. It’s a silent killer affecting the quality of life due to fractures and postural changes. In osteoporosis there is an imbalance between bone formation and bone resorption in favor of latter. Preventive measures and treatments are available to combat this evil. Counseling is the integral part of prevention as well as treatment of osteoporosis. Preventive strategy includes life style changes, exercise, intake of calcium and vitamin D, avoiding alcohol, smoking and excessive intake of salt. Estrogen therapy/estrogen+progesterone therapy (ET/EPT) is no longer recommended as a first-line therapy for the prevention of osteoporosis. They may be used in the therapy for osteoporosis in women under 60. Diagnosis and classification are made by assessment of BMD using DEXA or ultrasound and laboratory investigations. Management includes estimation of 10-year fracture risk using FRAX, life style and diet modification and pharmacological therapy. The drugs used in osteoporosis may be those that inhibit bone resorption—bisphosphonates, denosumab, calcitonin, SERMs, estrogen and progesterone—or that stimulate bone formation—PTH, Teriparatide. Combination therapies are not recommended as they do not have proven additional BMD/fracture benefits. No therapy should be indefinite in duration. There are no uniform recommendations to all patients. Duration decisions need to be individualized. While on treatment monitoring should be done with BMD assessment by DEXA/ultrasound and bone turnover markers.

Original languageEnglish
Pages (from-to)237-242
Number of pages6
JournalJournal of Obstetrics and Gynecology of India
Volume67
Issue number4
DOIs
Publication statusPublished - 01-08-2017

Fingerprint

Osteoporosis
Therapeutics
Estrogens
Bone and Bones
Life Style
Teriparatide
Diet Therapy
Selective Estrogen Receptor Modulators
Bone Remodeling
Bone Diseases
Calcitonin
Bone Resorption
Osteogenesis
Vitamin D
Progesterone
Hip
Counseling
Young Adult
Spine
Salts

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynaecology

Cite this

@article{cc39060f66f9423abaaabe8001f9c560,
title = "Osteoporosis Prevention and Management",
abstract = "Osteoporosis, defined by BMD at the hip or lumbar spine that is less than or equal to 2.5 standard deviations below the mean BMD of a young-adult reference population, is the most common bone disease in humans affecting both sexes and all races. It’s a silent killer affecting the quality of life due to fractures and postural changes. In osteoporosis there is an imbalance between bone formation and bone resorption in favor of latter. Preventive measures and treatments are available to combat this evil. Counseling is the integral part of prevention as well as treatment of osteoporosis. Preventive strategy includes life style changes, exercise, intake of calcium and vitamin D, avoiding alcohol, smoking and excessive intake of salt. Estrogen therapy/estrogen+progesterone therapy (ET/EPT) is no longer recommended as a first-line therapy for the prevention of osteoporosis. They may be used in the therapy for osteoporosis in women under 60. Diagnosis and classification are made by assessment of BMD using DEXA or ultrasound and laboratory investigations. Management includes estimation of 10-year fracture risk using FRAX, life style and diet modification and pharmacological therapy. The drugs used in osteoporosis may be those that inhibit bone resorption—bisphosphonates, denosumab, calcitonin, SERMs, estrogen and progesterone—or that stimulate bone formation—PTH, Teriparatide. Combination therapies are not recommended as they do not have proven additional BMD/fracture benefits. No therapy should be indefinite in duration. There are no uniform recommendations to all patients. Duration decisions need to be individualized. While on treatment monitoring should be done with BMD assessment by DEXA/ultrasound and bone turnover markers.",
author = "Pai, {Muralidhar V.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1007/s13224-017-0994-3",
language = "English",
volume = "67",
pages = "237--242",
journal = "Journal of Obstetrics and Gynecology of India",
issn = "0971-9202",
publisher = "Springer India",
number = "4",

}

Osteoporosis Prevention and Management. / Pai, Muralidhar V.

In: Journal of Obstetrics and Gynecology of India, Vol. 67, No. 4, 01.08.2017, p. 237-242.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Osteoporosis Prevention and Management

AU - Pai, Muralidhar V.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Osteoporosis, defined by BMD at the hip or lumbar spine that is less than or equal to 2.5 standard deviations below the mean BMD of a young-adult reference population, is the most common bone disease in humans affecting both sexes and all races. It’s a silent killer affecting the quality of life due to fractures and postural changes. In osteoporosis there is an imbalance between bone formation and bone resorption in favor of latter. Preventive measures and treatments are available to combat this evil. Counseling is the integral part of prevention as well as treatment of osteoporosis. Preventive strategy includes life style changes, exercise, intake of calcium and vitamin D, avoiding alcohol, smoking and excessive intake of salt. Estrogen therapy/estrogen+progesterone therapy (ET/EPT) is no longer recommended as a first-line therapy for the prevention of osteoporosis. They may be used in the therapy for osteoporosis in women under 60. Diagnosis and classification are made by assessment of BMD using DEXA or ultrasound and laboratory investigations. Management includes estimation of 10-year fracture risk using FRAX, life style and diet modification and pharmacological therapy. The drugs used in osteoporosis may be those that inhibit bone resorption—bisphosphonates, denosumab, calcitonin, SERMs, estrogen and progesterone—or that stimulate bone formation—PTH, Teriparatide. Combination therapies are not recommended as they do not have proven additional BMD/fracture benefits. No therapy should be indefinite in duration. There are no uniform recommendations to all patients. Duration decisions need to be individualized. While on treatment monitoring should be done with BMD assessment by DEXA/ultrasound and bone turnover markers.

AB - Osteoporosis, defined by BMD at the hip or lumbar spine that is less than or equal to 2.5 standard deviations below the mean BMD of a young-adult reference population, is the most common bone disease in humans affecting both sexes and all races. It’s a silent killer affecting the quality of life due to fractures and postural changes. In osteoporosis there is an imbalance between bone formation and bone resorption in favor of latter. Preventive measures and treatments are available to combat this evil. Counseling is the integral part of prevention as well as treatment of osteoporosis. Preventive strategy includes life style changes, exercise, intake of calcium and vitamin D, avoiding alcohol, smoking and excessive intake of salt. Estrogen therapy/estrogen+progesterone therapy (ET/EPT) is no longer recommended as a first-line therapy for the prevention of osteoporosis. They may be used in the therapy for osteoporosis in women under 60. Diagnosis and classification are made by assessment of BMD using DEXA or ultrasound and laboratory investigations. Management includes estimation of 10-year fracture risk using FRAX, life style and diet modification and pharmacological therapy. The drugs used in osteoporosis may be those that inhibit bone resorption—bisphosphonates, denosumab, calcitonin, SERMs, estrogen and progesterone—or that stimulate bone formation—PTH, Teriparatide. Combination therapies are not recommended as they do not have proven additional BMD/fracture benefits. No therapy should be indefinite in duration. There are no uniform recommendations to all patients. Duration decisions need to be individualized. While on treatment monitoring should be done with BMD assessment by DEXA/ultrasound and bone turnover markers.

UR - http://www.scopus.com/inward/record.url?scp=85018504450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018504450&partnerID=8YFLogxK

U2 - 10.1007/s13224-017-0994-3

DO - 10.1007/s13224-017-0994-3

M3 - Article

VL - 67

SP - 237

EP - 242

JO - Journal of Obstetrics and Gynecology of India

JF - Journal of Obstetrics and Gynecology of India

SN - 0971-9202

IS - 4

ER -